UnitedHealth Group Inc (UNH) Q2 FY2026: Reserves Aid Gains
Reserve-related medical-cost credits accounted for 43.0% of UnitedHealth’s first-half operating-profit increase, based on the author’s calculation from Note 4 of its 10-Q. These credits include favorable prior-year claims development and changes in premium-deficiency and loss-contract reserves. Quarterly revenue barely grew while profit rebounded. For this health insurer and care-services group, claims costs and membership matter more than headline sales.
1. Cash rose, but corporate access remains limited
Only $1.1B of $28.6B cash was available for general corporate use.
1-1. Receivables fell while goodwill barely moved
Acquisition-related assets remained substantial as receivables declined.
| Item ($M) | Dec. 31, 2025 | June 30, 2026 | Change |
|---|---|---|---|
| Cash and equivalents | 24,365 | 28,585 | 17.3% |
| Accounts receivable, net | 23,018 | 21,573 | -6.3% |
| Property, equipment and capitalized software, net | 10,762 | 10,762 | 0.0% |
| Goodwill | 110,499 | 110,645 | 0.1% |
| Other intangible assets, net | 20,474 | 19,749 | -3.5% |
| Total assets | 309,581 | 309,727 | 0.0% |
| Total liabilities | 207,883 | 203,778 | -2.0% |
| Redeemable noncontrolling interests | 1,608 | 1,436 | -10.7% |
| Total equity | 100,090 | 104,513 | 4.4% |
Changes are calculated from reported balances and rounded. Inventory and lease balances are not separately presented on this balance sheet. Receivables also reflect financing: the company sold $3.2B of receivables during the half.
1-2. Borrowings declined without fresh long-term issuance
Borrowings fell to $73,328M from $78,389M, combining current and long-term balances. A three-year maturity share and average coupon are not specified in this quarterly filing.
1-3. Retained earnings absorbed distributions
Retained earnings reached $100,957M: $95,603M + $11,764M in earnings attributable to common shareholders − $4,092M in dividends − $2,318M in repurchase allocations. The repurchase allocation to retained earnings is an equity-accounting amount, distinct from the $1,646M of cash repurchases in Section 3; the company also had forward repurchases settled after quarter-end. Additional paid-in capital fell from $559M to zero; common stock remained $9M. Accumulated other comprehensive losses deepened from $2,061M to $2,519M.
Sources: 10-Q, balance sheet p. 1; equity p. 5; Notes 1 and 5–6; liquidity p. 22.
2. Reserve benefits explain almost half the first-half improvement
Reserve-related medical-cost credits amplified the improvement in reported profitability.
2-1. The rebound still trails the earlier operating margin
The net-income rebound is larger than the improvement in operating profitability.
| Item ($M except margins) | H1 2024 | H1 2025 | H1 2026 | Annualized growth, 2024–26 |
|---|---|---|---|---|
| Revenue | 198,651 | 221,191 | 223,753 | 6.1% |
| Operating earnings | 15,806 | 14,269 | 16,981 | 3.7% |
| Operating margin | 8.0% | 6.5% | 7.6% | — |
| Consolidated net earnings | 3,200 | 10,046 | 12,151 | 94.9% |
| Consolidated net margin | 1.6% | 4.5% | 5.4% | — |
Margins divide each earnings row by revenue. Three observations span two years; annualized growth equals the square root of the 2026-to-2024 ratio, minus one. The earlier net-income base includes $8,311M of subsidiary-sale and held-for-sale losses.
Q2 operating earnings rose 55.2% ($7,991M/$5,150M − 1), against 0.4% revenue growth ($112,032M/$111,616M − 1). The calculated operating margin widened to 7.1% from 4.6%. Diluted EPS rose from $3.74 to $6.04.
The reserve bridge separates disclosed reserve-related credits from the reported profit increase.
| H1 reserve bridge ($M) | 2025 | 2026 |
|---|---|---|
| Favorable prior-year claims development | 320 | 1,250 |
| Medical-cost credits from changes in premium-deficiency and loss-contract reserves | 0 | 236 |
| Total benefit, calculated | 320 | 1,486 |
| Operating earnings less these benefits, calculated | 13,949 | 15,495 |
Incremental benefits were $1,166M against $2,712M operating-profit growth: 43.0%. Favorable prior-year claims development alone contributed $930M, or 34.3% of that growth. Note 4 attributes the 2026 prior-year development to a favorable respiratory illness season and other individually insignificant factors. The separate $236M represents changes in premium-deficiency and loss-contract reserves; the bridge does not establish that all of this amount came from lower estimates of ultimate claims obligations.
This sensitivity removes reserve-related credits, not all unusual items; reserve re-estimation is ordinary insurance accounting. Separately, excluding disclosed portfolio and restructuring effects gives H1 operating earnings of $16,943M: $16,981M − $191M + $415M − $75M − $187M, an author-calculated non-GAAP measure. These adjustments remove the portfolio gain, add back restructuring-related operating costs, and remove associated investment-income and medical-cost benefits. This alternative adjustment overlaps with the reserve bridge and should not be added to it.
2-2. The claims ratio fell while overhead rose
The medical care ratio—medical costs divided by premium revenue—fell to 86.7% from 89.4% in Q2. The operating-cost line excluding medical costs, products sold, and depreciation and amortization rose to $14,268M from $13,778M; the filing does not separate fixed and variable costs.
Sources: 2026 10-Q, operations p. 2; Notes 1 and 4; 2025 10-Q, operations p. 2.
3. Cash conversion improved, helped by payment timing
Operating cash strengthened more than earnings, but timing helped.
| Item ($M) | H1 2025 | H1 2026 | Change ($M) |
|---|---|---|---|
| Operating cash | 12,644 | 19,964 | 7,320 |
| Investing cash | -1,516 | -4,245 | -2,729 |
| Financing cash | -7,848 | -11,615 | -3,767 |
| June-end cash | 28,596 | 28,585 | -11 |
| Capital expenditure | 1,784 | 1,562 | -222 |
| Cash after property and software purchases | 10,860 | 18,402 | 7,542 |
| Operating cash / consolidated net earnings | 1.26x | 1.64x | — |
Cash after property and software purchases and cash-conversion ratios are calculated from reported figures. Cash conversion was 2.47x in H1 2024 ($7,890M/$3,200M), distorted by disposal losses. Current capital expenditure was 0.7% of revenue ($1,562M/$223,753M); maintenance versus growth spending is unspecified. Cash after capital expenditure is not freely distributable insurer cash.
Management cites government-payment timing and pharmacy rebates. Cash dividends and repurchases consumed $5,738M ($4,092M + $1,646M), alongside $4,813M in long-term debt repayments and net short-term borrowing repayments ($2,500M + $2,313M).
Sources: 2026 10-Q, cash flows p. 6 and discussion p. 22; 2025 10-Q, cash flows p. 6.
4. Better margins came with a smaller customer base
Membership contraction limits the recovery’s growth component.
| Indicator | Q2/June 2025 | Q2/June 2026 |
|---|---|---|
| Medical care ratio | 89.4% | 86.7% |
| UnitedHealthcare medical members (millions) | 50.115 | 48.525 |
| Medicare Advantage members (millions) | 8.350 | 7.565 |
| Optum Rx adjusted prescriptions (millions) | 414 | 387 |
Membership figures are June-end balances, converted from the filing’s thousands to millions; the medical care ratio and prescription counts cover Q2. Prescription counts are an operating measure, not adjusted earnings. Management expects further Medicare Advantage contraction. Medicaid reimbursement remains behind care costs.
Legal exposure is not fully quantified: Note 7 says the company often cannot estimate losses or ranges of losses for matters where a loss is reasonably possible or probable. The company also contests proposed IRS transfer-pricing adjustments; management considers its tax reserves adequate.
Source: 10-Q, Note 7; operating discussion pp. 17–21.
5. July commitments narrow the cash cushion
Profit improved, but reserve benefits and shrinking enrollment qualify the recovery. The earnings release nevertheless raised full-year 2026 guidance to reported EPS of $18.45–$18.95 and adjusted EPS of $19.50–$20.00. Management attributed the increase to year-to-date performance and an improved outlook for the remainder of the year. These are forecasts, with adjusted EPS presented on a non-GAAP basis. Source: UnitedHealth’s Q2 2026 earnings release.
Capital allocation extends beyond the June cash-flow statement: $2.0B of forward buybacks settled July 1, followed by $1.5B in acquisition cash paid July 2. Another $1.5B is payable within a year. These uses add funding demands beyond the quarter-end snapshot; they should not simply be subtracted from June’s cash available for general corporate use. Sustained recovery requires medical-cost control without relying on further reserve benefits.
Source: 10-Q, Notes 6–7 and capital resources p. 23.
This analysis is based on filings submitted to the U.S. Securities and Exchange Commission and is provided for informational purposes only. It is not investment advice.
